These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
121 related items for PubMed ID: 30773402
1. SPRi-based hemagglutinin quantitative assay for influenza vaccine production monitoring. Durous L, Julien T, Padey B, Traversier A, Rosa-Calatrava M, Blum LJ, Marquette CA, Petiot E. Vaccine; 2019 Mar 14; 37(12):1614-1621. PubMed ID: 30773402 [Abstract] [Full Text] [Related]
2. Antibody-independent surface plasmon resonance assays for influenza vaccine quality control. Serafin B, Kamen A, de Crescenzo G, Henry O. Appl Microbiol Biotechnol; 2024 Apr 24; 108(1):307. PubMed ID: 38656587 [Abstract] [Full Text] [Related]
3. Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies. Verma S, Soto J, Vasudevan A, Schmeisser F, Alvarado-Facundo E, Wang W, Weiss CD, Weir JP. PLoS One; 2017 Apr 24; 12(4):e0175733. PubMed ID: 28423025 [Abstract] [Full Text] [Related]
4. Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency. Khurana S, King LR, Manischewitz J, Coyle EM, Golding H. Vaccine; 2014 Apr 17; 32(19):2188-97. PubMed ID: 24613520 [Abstract] [Full Text] [Related]
5. Hemagglutinin Quantitative ELISA-based Potency Assay for Trivalent Seasonal Influenza Vaccine Using Group-Specific Universal Monoclonal Antibodies. Chae W, Kim P, Kim H, Cheong YC, Kim YS, Kang SM, Seong BL. Sci Rep; 2019 Dec 23; 9(1):19675. PubMed ID: 31873147 [Abstract] [Full Text] [Related]
6. Inactivated influenza vaccine stress can affect in vitro potency assay relationship to immunogenicity. Wen Y, Palladino G, Xie Y, Ferrari A, Settembre EC. Vaccine; 2018 May 17; 36(21):3010-3017. PubMed ID: 29680201 [Abstract] [Full Text] [Related]
7. Determination of the potency of a cell-based seasonal quadrivalent influenza vaccine using a purified primary liquid standard. Takahashi H, Fujimoto T, Horikoshi F, Uotani T, Okutani M, Shimasaki N, Hamamoto I, Odagiri T, Nobusawa E. Biologicals; 2020 Nov 17; 68():32-39. PubMed ID: 33023810 [Abstract] [Full Text] [Related]
13. Hemagglutinin and neuraminidase containing virus-like particles produced in HEK-293 suspension culture: An effective influenza vaccine candidate. Venereo-Sanchez A, Gilbert R, Simoneau M, Caron A, Chahal P, Chen W, Ansorge S, Li X, Henry O, Kamen A. Vaccine; 2016 Jun 17; 34(29):3371-80. PubMed ID: 27155499 [Abstract] [Full Text] [Related]
14. A monoclonal antibody-based immunoassay for measuring the potency of 2009 pandemic influenza H1N1 vaccines. Schmeisser F, Vasudevan A, Soto J, Kumar A, Williams O, Weir JP. Influenza Other Respir Viruses; 2014 Sep 17; 8(5):587-95. PubMed ID: 25087462 [Abstract] [Full Text] [Related]
20. Potency under pressure: the impact of hydrostatic pressure on antigenic properties of influenza virus hemagglutinin. Eichelberger SL, Sultana I, Gao J, Getie-Kebtie M, Alterman M, Eichelberger MC. Influenza Other Respir Viruses; 2013 Nov 17; 7(6):961-8. PubMed ID: 23496824 [Abstract] [Full Text] [Related] Page: [Next] [New Search]